Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics

The Key Fabry Disease Companies in the market include - Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others.
DelveInsight's "Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Fabry Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Fabry Disease Market Forecast [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Fabry Disease Market Report:

*
The Fabry Disease market size was valued ~USD 1,306 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In December 2024, Exegenesis Bio, a global clinical-stage gene therapy company, announced that the U.S. FDA has granted Orphan Drug Designation (ODD) to EXG110, an innovative gene therapy for Fabry disease-a rare lysosomal disorder characterized by excessive lipid accumulation in tissues, leading to renal failure, cardiac complications, and strokes.

*
In 2022, the U.S. had the largest Fabry Disease market size among the 7MM, valued at approximately USD 625 million, with projections for further growth by 2032

*
Within the European Union, the United Kingdom and Italy represent the largest market shares, with figures reaching USD 158 million and USD 150 million respectively in 2022. Conversely, Spain holds the lowest market position during the same period, with a recorded figure of USD 44 million.

*
In 2022, the Fabry Disease market size reached its peak in the US among the seven major markets (7MM), amounting to approximately USD 625 million. This figure is projected to continue rising through to 2032.

*
In 2022, there were a total of 15,290 diagnosed prevalent cases of Fabry Disease in the seven major markets (7MM), with the highest number of cases recorded in the United States. The EU4 countries and the UK accounted for 5,245 cases, while Japan had 1,690 cases.

*
In the US, 4,345 males and 4,011 females were affected by Fabry disease in 2022. These numbers are expected to rise by 2032.

*
In 2022, the UK had the highest number of diagnosed prevalent cases of Fabry Disease among the EU4 and the UK, with approximately 58% of the cases being female and 42% male. These numbers are anticipated to change during the forecast period.

*
DelveInsight analysts reported that the diagnosed prevalent cases of Fabry Disease in 2022 were categorized into classic and late-onset phenotypes. There were 3,342 cases of the classic phenotype and 5,013 cases of the late-onset phenotype in the seven major markets (7MM).

*
Key Fabry Disease Companies: Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others

*
Key Fabry Disease Therapies: ELFABRIO (PRX-102), Venglustat, Isaralgagene civaparvovec (ST-920), PRX-102, AVR-RD-01, Venglustat, ST -920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others

*
The Fabry Disease epidemiology based on gender analyzed that Fabry Disease is more prevalent in males than females in the United States

*
The Fabry Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Fabry Disease pipeline products will significantly revolutionize the Fabry Disease market dynamics.

Fabry Disease Overview

Fabry disease is a rare genetic disorder caused by mutations in the GLA gene, which leads to a deficiency or malfunction of the enzyme alpha-galactosidase A. This enzyme is crucial for breaking down a fatty substance called globotriaosylceramide (Gb3 or GL-3) in the body's cells. When alpha-galactosidase A is deficient or dysfunctional, Gb3 accumulates in various tissues and organs, leading to a wide range of symptoms.

Get a Free sample for the Fabry Disease Market Report:

https://www.delveinsight.com/report-store/fabry-disease-market [https://www.delveinsight.com/report-store/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Fabry Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Fabry Disease Epidemiology Segmentation:

The Fabry Disease market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Fabry Disease

*
Prevalent Cases of Fabry Disease by severity

*
Gender-specific Prevalence of Fabry Disease

*
Diagnosed Cases of Episodic and Chronic Fabry Disease

Download the report to understand which factors are driving Fabry Disease epidemiology trends @ Fabry Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Fabry Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Fabry Disease market or expected to get launched during the study period. The analysis covers Fabry Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Fabry Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Fabry Disease Therapies and Key Companies

*
ELFABRIO (PRX-102): Chiesi and Protalix Biotherapeutics

*
Venglustat: Sanofi Genzyme

*
Isaralgagene civaparvovec (ST-920): Sangamo Therapeutics

*
PRX-102: Protalix Biotherapeutics

*
AVR-RD-01: AVROBIO

*
Venglustat: Sanofi Genzyme

*
ST-920: Sangamo Therapeutics

*
FLT190: Freeline Therapeutics

*
4D-310: 4D Molecular Therapeutics

*
Lucerastat: Idorsia Pharmaceuticals

*
Moss-aGal: Greenovation Biotech GMBH

*
PRX-102: ICON plc

*
pegunigalsidase alfa: Chiesi Farmaceutici S.p.A.

*
migalastat: Amicus Therapeutics

*
Agalsidase alfa: Shire

Discover more about therapies set to grab major Fabry Disease market share @ Fabry Disease Treatment Market [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Fabry Disease Market Strengths

*
Emphasis on NBS to detect Fabry Disease at an early stage allows for timely treatment with better risk- benefit assessment.

*
The growing Fabry Disease pool is expected to propel the treatment market, adding opportunities for new pharma players.

Fabry Disease Market Opportunities

*
Development of potential biomarkers allows tracking the severity and predicting the progression of the disease, as well as checking the effectiveness of therapeutic intervention.

*
The shortcomings of enzyme replacement therapy, partly due to antibody formation, can be alleviated by combining new oral therapy approaches.

Scope of the Fabry Disease Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Fabry Disease Companies: Chiesi and Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Protalix Biotherapeutics, AVROBIO, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, Greenovation Biotech GMBH, ICON plc, Chiesi Farmaceutici S.p.A., Amicus Therapeutics, Shire, and others

*
Key Fabry Disease Therapies: ELFABRIO (PRX-102), Venglustat, Isaralgagene civaparvovec (ST-920), PRX-102, AVR-RD-01, Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, PRX-102, pegunigalsidase alfa, migalastat, Agalsidase alfa, and others

*
Fabry Disease Therapeutic Assessment: Fabry Disease current marketed and Fabry Disease emerging therapies

*
Fabry Disease Market Dynamics: Fabry Disease market drivers and Fabry Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Fabry Disease Unmet Needs, KOL's views, Analyst's views, Fabry Disease Market Access and Reimbursement

To know more about Fabry Disease companies working in the treatment market, visit @ Fabry Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/fabry-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Fabry Disease Market Report Introduction

2. Executive Summary for Fabry Disease

3. SWOT analysis of Fabry Disease

4. Fabry Disease Patient Share (%) Overview at a Glance

5. Fabry Disease Market Overview at a Glance

6. Fabry Disease Disease Background and Overview

7. Fabry Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Fabry Disease

9. Fabry Disease Current Treatment and Medical Practices

10. Fabry Disease Unmet Needs

11. Fabry Disease Emerging Therapies

12. Fabry Disease Market Outlook

13. Country-Wise Fabry Disease Market Analysis (2019-2032)

14. Fabry Disease Market Access and Reimbursement of Therapies

15. Fabry Disease Market Drivers

16. Fabry Disease Market Barriers

17. Fabry Disease Appendix

18. Fabry Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=fabry-disease-market-growth-projections-20232032-delveinsight-analysis-sanofi-genzyme-sangamo-therapeutics-freeline-therapeutics-avrobio-4d-molecular-therapeutics]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.